Chengdu Olymvax Hits Day Low of CNY 31.10 Amid Price Pressure

Chengdu Olymvax Biopharmaceuticals, Inc. experienced a notable decline today, with the stock dropping by 3.4% on June 2, 2026. The stock reached an intraday low of CNY 31.10, reflecting a challenging trading session. Over the past week, the stock has seen a more significant downturn, with a decrease of 14.12%, contrasting with the China Shanghai Composite's decline of only 1.7%. Despite today's performance, Chengdu Olymvax has shown resilience over the longer term, boasting a remarkable 74.55% increase over the past year, significantly outperforming the China Shanghai Composite, which gained 21.74% during the same period. Year-to-date, the stock has risen by 25.47%, further highlighting its strong market position. Financial metrics indicate a robust operational framework, with a net sales growth of 25.38% reported in September. The company has also achieved a high return on capital employed (ROCE) of 6.86% and an impressive interest coverage ratio of 1,289.5. These indicators suggest that while the stock faces short-term volatility, it maintains a solid foundation for future performance.